#KRAS 🎯cancer patient group for reliable Knowledge Research Advocacy & Survivorship. Survival of the strategic. #KickCancersKRAS - 🚫 #KRASholes
International, ALL RAS cancers
Joined February 2020
- Tweets5.1K
- Following4.9K
- Followers4.2K
- Likes12.5K
Pinned Tweet
At @ASCO #GI26 we presented our KRAS KICKERS Trial Finder.
Personalized: KRAS G12D, CRC, US trials
Results (in 4 minutes): 20 trials
go to KRASHUB.ORG
in beta - would love your feedback
abstract
asco.org/abstracts-presentat…
FYI:
G12V - 8 trials for CRC
G12R - 7 trials for CRC
Catching up on #AACR26 - last 5.5 hours of an open platform.
Revisiting some, watching some for the first time.
Patient Advocate Poster Symposium: Advancing Cancer Research Through Patient and Community Partnerships
@paspears88 @coloncancergal
Annie Ellis (@Stigetta), Michael Casaus and Lourdes Baezconde-Garbanati
@AACR
- hoping platform remains open tomorrow as well!
Project Cure CRC: a patient-powered ecosystem uniting data, discovery and accelerating cures for colorectal cancer
@LeadFromBehind getting a WEBBIE win with non-traditional screening messages!
Cure CRC - innovative platform, transformative goals!
@coloncancergal @CCAlliance
slide from @Stigetta
MATCHMAKERS Cancer Grand Challenge Team: partnership and purpose to maximize patient research advocate involvement in collaborative preclinical research
@CancerGrand
KRAS Kickers retweeted
KRASi is moving into neoadjuvant treatment of pancreatic cancer and showed promising results in different combinations: #ESMO26 KRAS G12Di inhibitor HRS-4642 combined with chemo, IO, or anti-EGFR trials in China. More options for pancreatic patients are coming.
KRAS Kickers retweeted
🔥Ph2 Peri-operative RASi (HRS-4642, G12D)+ GnP +/-adebrelimab (PD-L1)
➡️two cohorts n=60 #PDAC
➡️safety- mainly haem, none precluded surgery
➡️ORR 63% & 87%;MPR in 17%
➡️R0 resection rate 100%
✅6 mth EFS rate 87% & 96%
➡️100% ⬇️CA19.9; OS pending
@myESMO #ESMO26 @OncoAlert
KRAS Kickers retweeted
HRS-4642 is a KRAS G12D inhibitor from Jiangsu Hengrui Pharmaceuticals in China. Phase 2, two-arm trial with GnP (D1/8, q3w) and +/- anti-PD-1, for R/BR PDAC, perioperatively. ORR was 63%, and 87% w/PD-1, presented at #EMSO26 today. No interruption to surgery. 6-mo EFS 87%.🚀
KRAS Kickers retweeted
Chemotherapy-free phase 1/2 trial of HRS-4642 plus adebrelimab in previously treated metastatic KRAS G12D-mutant pancreatic cancer dlvr.it/TVwkLz
KRAS Kickers retweeted
New degrader from Nurix looks interesting: NRX-0305 demonstrated antitumour activity across a wide range of Class 1 BRAF inhibitor-resistant and Class 2/3 mutant PDX models #aacr26
KRAS Kickers retweeted
Frank McCormick, PhD, FAACR, helped lay the foundation for targeting KRAS, one of the most common drivers of cancer. Learn how his research continues to shape new approaches to cancer treatment. brnw.ch/21x6NOT
Catching up on #AACR26 - last 10.5 hours of an open platform.
Revisiting some, watching some for the first time.
Advances and future therapeutic strategies for BRAF‑mutated and RAS‑driven colorectal cancer with Dr. @skopetz of @UTMDAnderson
Slide re Daraxonrasib in CRC has been so incredibly useful in answering patient questions
The RAS Agents Slide was a go-to resource for months!
@AACR
- hoping platform remains open tomorrow as well!
Catching up on #AACR26 - last 12 hours of an open platform.
Revisiting some, watching some for the first time.
First up @Aiims1742 and @DrShubhamPant Danielle Engel and William Freed-Pastor
@AACR - hoping platform remains open tomorrow as well!
And now the story becomes a bit science fiction..
but perhaps prophetic!
#KrasCleanse - first use of this hashtag on Twitter.
KRAS Kickers retweeted
Great commentary on evolving role of RT in era of RAS inhibition in pancreas cancer.
Novel drugs reshaping PDAC treatment landscape provides opportunities for all modalities to adapt & advance.
We are working on amending GI011 to incorporate RAS inhibitors.
In this @OncJournal commentary, @EileenMOReilly and I highlight emerging preclinical evidence of synergy between RAS inhibition and RT in PDAC and make the case for prospective clinical trials evaluating this combination across the disease spectrum
academic.oup.com/oncolo/arti…
